Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Anatomical significance in aortoiliac occlusive disease
Wooten, Candace, Hayat, Munawar, Plessis, Maira du , Cesmebasi, Alper , Koesterer, Michael, Daly, Kevin P. , Matusz, Petru, Tubbs, R. Shane , Loukas, Marios , Hayat, Munawar

Clinical Anatomy | July 25, 2014 | Volume: 27 | Issue: 8 | Pages: 1264-1274

10.1002/ca.22444 | PMID 25065617 Get It

Aortoiliac occlusive disease is a subset of peripheral arterial disease involving an atheromatous occlusion of the infrarenal aorta, common iliac arteries, or both. The disease, as it is known today, was described by the French surgeon René Leriche as a thrombotic occlusion of the end of the aorta. Leriche successfully linked the anatomic location of the occlusion with a unique triad of symptoms, including claudication, impotence, and decreased peripheral pulses. The anatomical location of the atheromatous lesions also has a direct influence on classification of the disease, as well as choice of treatment modality. Considering its impact on diagnosis and treatment, we aimed to provide a detailed understanding of the anatomical structures involved in aortoiliac occlusive disease. Familiarity with these structures will aid the physician in interpretation of radiologic images and surgical planning. Clin. Anat. 27:1264–1274, 2014. © 2014 Wiley Periodicals, Inc.
Ano1, a Ca2+‐activated Cl− channel, coordinates contractility in mouse intestine by Ca2+ transient coordination between interstitial cells of Cajal
Singh, Raman Deep , Gibbons, Simon J. , Saravanaperumal, Siva Arumugam , Du, Peng , Hennig, Grant W. , Eisenman, Seth T., Mazzone, Amelia , Hayashi, Yujiro , Cao, Chike , Stoltz, Gary J., Ördög, Tamás , Rock, Jason R. , Harfe, Brian D. , Szurszewski, Joseph H., Farrugia, Gianrico , Gibbons, S J , Mazzone, Amelia

The Journal of Physiology | July 25, 2014 | Volume: 592 | Issue: 18 | Pages: 4051-4068

10.1113/jphysiol.2014.277152 | PMID 25063822 Get It

Key points Ano1, a Ca2+‐activated Cl− channel, is expressed in interstitial cells of Cajal (ICC) throughout the gut. We report here that it is required to maintain coordinated Ca2+ transients within myenteric ICC of mouse small intestine. Ca2+ transients in Ano1 WT mice were rhythmic and coordinated whereas uncoordinated Ca2+ transients were seen in knockout mice. Ca2+ transients were un‐coordinated following pharmacological block of Ano1 in WT mice using niflumic acid, 5‐nitro‐2‐(3‐phenylpropylamino) benzoic acid and 4,4′‐diisothiocyanato‐2,2′‐stilbenedisulfonic acid disodium salt. Transient knockdown of Ano1 in organotypic cultures with short hairpin RNA to Ano1 in WT tissues also caused loss of coordinated Ca2+ transients. Contractility of Ano1 knockout mouse intestinal segments in organ bath experiments was significantly decreased, less coordinated and non‐rhythmic. Spatiotemporal maps from knockout mouse small intestine also showed loss of phasic contractile activity. This study provides important information on the basic mechanisms driving coordinated contractile activity in the gastrointestinal tract. AbstractInterstitial cells of Cajal (ICC) are pacemaker cells that generate electrical activity to drive contractility in the gastrointestinal tract via ion channels. Ano1 (Tmem16a), a Ca2+‐activated Cl− channel, is an ion channel expressed in ICC. Genetic deletion of Ano1 in mice resulted in loss of slow waves in smooth muscle of small intestine. In this study, we show that Ano1 is required to maintain coordinated Ca2+ transients between myenteric ICC (ICC‐MY) of small intestine. First, we found spontaneous Ca2+ transients in ICC‐MY in both Ano1 WT and knockout (KO) mice. However, Ca2+ transients within the ICC‐MY network in Ano1 KO mice were uncoordinated, while ICC‐MY Ca2+ transients in Ano1 WT mice were rhythmic and coordinated. To confirm the role of Ano1 in the loss of Ca2+ transient coordination, we used pharmacological inhibitors of Ano1 activity and shRNA‐mediated knock down of Ano1 expression in organotypic cultures of Ano1 WT small intestine. Coordinated Ca2+ transients became uncoordinated using both these approaches, supporting the conclusion that Ano1 is required to maintain coordination/rhythmicity of Ca2+ transients. We next determined the effect on smooth muscle contractility using spatiotemporal maps of contractile activity in Ano1 KO and WT tissues. Significantly decreased contractility that appeared to be non‐rhythmic and uncoordinated was observed in Ano1 KO jejunum. In conclusion, Ano1 has a previously unidentified role in the regulation of coordinated gastrointestinal smooth muscle function through coordination of Ca2+ transients in ICC‐MY.
The Hidden Consequences of Ventilator Management Decisions
Hubmayr, Rolf D., Oeckler, Richard A.

Respiratory Care | July 25, 2014 | Volume: 59 | Issue: 8 | Pages: 1302-1305

10.4187/respcare.03366 | PMID 25233518 Get It

In the following perspective, we will highlight seemingly remote, downstream consequences of common ventilator management decisions. For example, a change in PEEP may alter venous return, blood pressure, cardiac output, arterial and venous blood gas tensions, metabolic rate, respiratory sensations, breathing pattern, and the work of breathing. If providers consider any of these changes dangerous or maladaptive, they may initiate additional interventions in the form of vasoactive agents, intravenous fluids, and/or sedatives, all of which have their own risk/benefit profile. The approach to such co-interventions is rarely addressed even in well-designed large clinical trials. Therefore, it is often impossible to infer intervention-specific mechanisms of action and/or identify the phenotype of responders and nonresponders in such trials. On the flip side, in preclinical research intended to uncover mechanisms, experimental animals are rarely treated the way a critically ill patient would be. For respiratory therapists, this knowledge gap stresses the imperative to think beyond the lungs and to communicate ventilator management decisions with all members of the healthcare team.
Environmental Factors in Primary Biliary Cirrhosis
Juran, Brian D., Lazaridis, Konstantinos N.

Seminars in Liver Disease | July 24, 2014 | Volume: 34 | Issue: 03 | Pages: 265-272

10.1055/s-0034-1383726 | PMID 25057950 Get It

Metformin Pharmacogenomics: Biomarkers to Mechanisms
Wang, Liewei , Weinshilboum, Richard M. , Weinshilboum, Richard, Weinshilboum, Richard M.

Diabetes | July 24, 2014 | Volume: 63 | Issue: 8 | Pages: 2609-2610

10.2337/db14-0609 | PMID 25060891 Get It

Scurvy presenting as hematochezia
Palmer, William , Vazquez-Roche, Maria, Palmer, William C.

Endoscopy | July 24, 2014 | Volume: 46 | Issue: S 01 | Pages: E292-E292

10.1055/s-0034-1365815 | PMID 25058817 Get It

Imatinib in Pulmonary Arterial Hypertension: C‐Kit Inhibition
Farha, Samar , Dweik, Raed A. , Rahaghi, Franck , Benza, Raymond L. , Frantz, Robert P. , Torres, Fernando , Quinn, Deborah A., Comhair, Suzy, Erzurum, Serpil C. , Asosingh, Kewal, Frantz, Robert, Benza, Raymond L. , Hassoun, Paul M. , Frantz, Robert P

Pulmonary Circulation | July 24, 2014 | Volume: 4 | Issue: 3 | Pages: 452-455

10.1086/677359 | PMID 25621158 Get It

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by severe remodeling of the pulmonary artery resulting in increased pulmonary artery pressure and right ventricular hypertrophy and, ultimately, failure. Bone marrow–derived progenitor cells play a critical role in vascular homeostasis and have been shown to be involved in the pathogenesis of PAH. A proliferation of c‐Kit+ hematopoietic progenitors and mast cells has been noted in the remodeled vessels in PAH. Imatinib, a tyrosine kinase inhibitor that targets c‐Kit, has been shown to be beneficial for patients with PAH. Here we hypothesize that the clinical benefit of imatinib in PAH could be related to c‐Kit inhibition of progenitor cell mobilization and maturation into mast cells. As a corollary to the phase 3 study using imatinib in PAH, blood samples were collected from 12 patients prior to starting study drug (baseline) and while on treatment at weeks 4 and 24. Eight were randomized to imatinib and 4 to placebo. Circulating c‐Kit+ and CD34+ CD133+ hematopoietic progenitors as well as biomarkers of mast cell numbers and activation were measured. Circulating CD34+ CD133+ and c‐Kit+ progenitor cells as well as c‐Kit+/CD34+ CD133+ decreased with imatinib therapy (all P < 0.05). In addition, total tryptase, a marker of mast cell load, dropped with imatinib therapy (P = 0.02) and was related to pulmonary vascular resistance (R = 0.7, P = 0.02). The findings support c‐Kit inhibition as a potential mechanism of action of imatinib in PAH and suggest that tryptase is a potential biomarker of response to therapy.
Practice Trends in Patients with Persistent Detectable Thyroglobulin and Negative Diagnostic Radioiodine Whole Body Scans: A Survey of American Thyroid Association Members
Smallridge, Robert C., Diehl, Nancy N. , Bernet, Victor

Thyroid® | July 24, 2014 | Volume: 24 | Issue: 10 | Pages: 1501-1507

10.1089/thy.2014.0043 | PMID 25058708 Get It

Background: Management of patients with thyroglobulin (Tg)-positive/scan-negative thyroid cancer remains challenging. American Thyroid Association (ATA) guidelines recommend potential use of empiric 131 I therapy and various scanning modalities, but no standard for managing such cases exists. Methods: We surveyed ATA members to assess current practice in management of patients with Tg-positive/scan-negative disease. Members participated in a web-based survey of six case scenarios of Tg elevations but iodine scan negativity. Results: A total of 288 ATA members (80% male) participated. Patient age, sex, and basal and stimulated Tg varied between the cases. Respondents were asked their opinion regarding empiric 131 I therapy use, including 131 I dose, use and duration of low-iodine diet, thyroxine withdrawal or recombinant human thyrotropin (rhTSH), and utilization of additional imaging (neck ultrasound (US) or positron emission tomography/computed tomography (PET/CT)) and reconsideration of 131 I therapy. Between 16% and 51% recommended initial use of empiric 131 I for the various scenarios. The majority chose a 131 I dose between 75 and 150 mCi, and 73% employed a low-iodine diet for two or more weeks. Preference between thyroxine withdrawal versus rhTSH was evenly split. More than 98% obtained a neck US if empiric 131 I was not given; 52–89% would proceed to PET/CT if US was negative. Only 44% used rhTSH stimulation in PET scan preparation. 131 I use was more common with stimulated Tg significantly >10 ng/mL. 131 I therapy was slightly more likely with PET-positive (56%) than PET-negative status (45%). Respondents were split regarding empiric 131 I if basal and stimulated Tg increased ≥150% over two years. Providers in North America less commonly utilized 131 I treatment than those from other areas. In the face of possible heterophilic antibody interference in the Tg assay, the majority did not recommend 131 I therapy. Conclusions: Empiric 131 I therapy is still utilized for patients with Tg-positive/scan-negative disease. Neck US is frequently used to further evaluate such cases as 18 FDG-PET/CT, albeit the latter is used somewhat less often. Use of 131 I therapy correlated with the degree of Tg elevation or development of Tg antibodies, and was recommended more commonly with PET-positive than PET-negative status in patients with lower Tg levels. 131 I was less commonly used by providers within North America.
In Vivo Comparison of Radiation Exposure of Dual-Energy CT Versus Low-Dose CT Versus Standard CT for Imaging Urinary Calculi
Jepperson, Maria A., Cernigliaro, Joseph G. , Morin, Richard L. , Haley, William E. , Thiel, David D. , Ibrahim, El‐Sayed H.

Journal of Endourology | July 24, 2014 | Volume: 29 | Issue: 2 | Pages: 141-146

10.1089/end.2014.0026 | PMID 25058059 Get It

Purpose: Dual-energy computed tomography (DECT) is an emerging imaging modality with the unique capability of determining urinary stone composition. This study compares radiation exposure of DECT, standard single-energy CT (SECT), and low-dose renal stone protocol single-energy CT (LDSECT) for the evaluation of nephrolithiasis in a single in vivo patient cohort. Materials and Methods: Following institutional review board (IRB) approval, we retrospectively reviewed 200 consecutive DECT examinations performed on patients with suspected urolithiasis over a 6-month period. Of these, 35 patients had undergone examination with our LDSECT protocol, and 30 patients had undergone examination of the abdomen and pelvis with our SECT imaging protocol within 2 years of the DECT examination. The CT dose index volume (CTDI vol ) was used to compare radiation exposure between scans. Image quality was objectively evaluated by comparing image noise. Statistical evaluation was performed using a Student's t -test. Results: DECT performed at 80/140 kVp and 100/140 kVp did not produce a significant difference in radiation exposure compared with LDSECT ( p =0.09 and 0.18, respectively). DECT performed at 80/140 kVp and 100/140 kVp produced an average 40% and 31%, respectively, reduction in radiation exposure compared with SECT ( p <0.001). For patients imaged with the 100/140 kVp protocol, average values for images noise were higher in the LDSECT images compared with DECT images ( p <0.001) and there was no significant difference in image noise between DECT and SECT images in the same patient ( p =0.88). Patients imaged with the 80/140 kVp protocol had equivocal image noise compared with LDSECT images ( p =0.44), however, DECT images had greater noise compared with SECT images in the same patient ( p <0.001). Of the 75 patients included in the study, stone material was available for 16; DECT analysis correctly predicted stone composition in 15/16 patients (93%). Conclusion: DECT provides knowledge of stone composition in addition to the anatomic information provided by LDSECT/SECT without increasing patient radiation exposure and with minimal impact on image noise.